
    
      This clinical trial is an exploratory study, and does not calculate the subject number based
      on statistical assumptions, and enrolls 50 subjects per group and a total of 100 subjects are
      registered to evaluate the effect of improving blood glucose variability in type 2 patients
      with anagliptin 100 mg twice a day(BID) and sitagliptin 100 mg once a day(QD).
    
  